Delivery Order SPE2DB22D1017-SPE2DB25FG8SX
- Not listed
- This delivery order, valued at $142,433.37, was awarded to AmerisourceBergen Drug Corp on July 21, 2025, under a firm fixed-price arrangement with an ultimate completion date of July 22, 2025. The contract is executed through the Defense Logistics Agency's Medical Supply Chain, a division of the Department of Defense responsible for pharmaceutical and medical product distribution to military and veteran healthcare systems. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $41,480.40 to AmerisourceBergen Drug Corp on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award carries no set-aside designation...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $27,577 to AmerisourceBergen Drug Corp on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The award was made on a competitive basis with no set-aside...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $39,192.65 to AmerisourceBergen Drug Corp on July 28, 2025, with a completion date of July 29, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion through December 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $43,623.36 to AmerisourceBergen Drug Corp on August 9, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order, which represents a child contract under a larger indefinite delivery vehicle, was competitively awarded with no set-aside designation. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen maintains...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $82,029.40 by the Defense Logistics Agency's Medical Supply Chain on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency Medical Supply Chain awarded a $935,623.49 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 26, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a child award under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $10,567.60 to AmerisourceBergen Drug Corp on July 28, 2025, with an ultimate completion date of the same day. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was not set-aside and was competitively awarded, reflecting...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $179,628.39 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. This firm fixed-price delivery order, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award carries no set-aside...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $5,403.30 to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, on August 4, 2025. This firm fixed-price delivery order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by August 5, 2025. The award was made through competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8SXDelivery Order
The Defense Logistics Agency awarded a $1,154.79 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Qualiptapeptide 60 mg tablets (30-count) with an ultimate completion date of August 4, 2025. This is a non-set-aside competitive award issued to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the products will be delivered. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle that runs through December 2026 and enables the company to supply pharmaceuticals and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves the Defense Health Agency and other government healthcare systems through competitively awarded contracts with the DLA Medical Supply Chain. The company's extensive portfolio of federal contracts demonstrates its capability to fulfill diverse pharmaceutical procurement requirements, ranging from small transactions to substantial orders, and includes specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This award is part of the DLA's broader pharmaceutical procurement strategy, which includes planning for multiple-award Pharmaceutical Prime Vendor Global Program Generation V contracts across separate regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/1/25 |